It was announced last week that Joana Simões Correia, the Executive Director of Exogenus Therapeutics (Exo-T) is one of the Young Transatlantic Innovation Leaders of 2017.
The Young Transatlantic Innovative Leaders Initiative Fellowship is the flagship program of the Young Transatlantic Innovation Leaders Initiative (YTILI) of the U.S. Department of State and is supported in its implementation by the German Marshall Fund of the United States (GMF). Out of almost 650 applicants, the YTILI Fellowship was attributed to 100 young European entrepreneurs, who will engage in a series of professional development and leadership activities that are designed to support the growth and development of commercial and social business ventures in their home communities. Through the YTILI Fellowship, the fellows will build networks, linkages and lasting partnerships to attract investments and support for their entrepreneurial ventures.
Exogenus Therapeutics is dedicated to the development of a biologic advanced therapy for chronic wounds. US represents the biggest market opportunity for the product under development, Exo-Wound. The major players acting in wound management sector are localized in the US, it is a privileged localization for Clinical Development due to the high level of the Research Centres and the increased number of leading experts, while it is also the strongest hub worldwide for biotech companies to grow.
Joana Simões Correia, Executive Director of Exo-T, stated that “I am very proud to be selected for this international program focused on innovation leadership. It reflects the internationalization potential of our company, and recognizes the level of the disruptive innovation we are exploiting. I hope to bring value to the Portuguese biotech ecosystem through networking and established partnerships in the US. I believe that this opportunity will allow Exo-T to attract interest from transatlantic stakeholders, ultimately aiding our progress through the development of our business plan.”